Asset profile

casdatifan · Arcus Biosciences (RCUS)

Indication: clear cell renal cell carcinoma (ccRCC)
Also known as: AB521, ARC-20

Company

Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zi…

Start live analysis of RCUS Run 8-agent AI analysis

On the calendar

Oct 2026

Oct 20, 2026

2 days ago

RCUSArcus Biosciences

Arcus to present new casdatifan data in ccRCC at Oct 20 2026 investor event

Conference presentationCompany press release

Nov 2027

Nov 2, 2027

in 376 days

RCUSArcus Biosciences

casdatifan: Phase 1/Phase 2 trial NCT07227415 expected to finish collecting primary-endpoint data (topline results usually follow)

Trial primary completionClinicalTrials.gov

Jan 2028

Jan 31, 2028

in 466 days

RCUSArcus Biosciences

casdatifan: Phase 2 trial NCT07397611 expected to finish collecting primary-endpoint data (topline results usually follow)

Trial primary completionClinicalTrials.gov

Apr 2028

~ Apr 2028

RCUSArcus Biosciences

casdatifan: Phase 3 trial NCT07011719 expected to finish collecting primary-endpoint data (topline results usually follow)

Trial primary completionClinicalTrials.govMonth only

Nov 2029

Nov 28, 2029

in 1133 days

RCUSArcus Biosciences

casdatifan: Phase 1/Phase 2 trial NCT07293351 expected to finish collecting primary-endpoint data (topline results usually follow)

Trial primary completionClinicalTrials.gov

Timeline

Newest first.

Oct 20, 2026

12:33 PM

RCUSArcus Biosciences

Arcus presents updated casdatifan data from ARC-20 in 1L/2L/late-line ccRCC at conference

Conference presentationSEC 8-K

Oct 20, 2026

12:30 PM

RCUSArcus Biosciences

Arcus Reports Positive ARC-20 Data for Casdatifan in 1L/2L/Late-Line ccRCC

Topline resultsCompany press release Open record

Oct 8, 2026

03:20 PM

RCUSArcus Biosciences

casdatifan · NCT07227415 registry update

Trial registry changeClinicalTrials.gov

Sep 29, 2026

03:21 PM

RCUSArcus Biosciences

casdatifan · NCT07011719 registry update

Trial registry changeClinicalTrials.gov

Sep 23, 2026

03:20 PM

RCUSArcus Biosciences

casdatifan · NCT07293351 registry update

Trial registry changeClinicalTrials.gov

Sep 22, 2026

12:30 PM

RCUSArcus Biosciences

Arcus to present new casdatifan data in ccRCC at Oct 20 2026 investor event

Conference presentationCompany press release

Readiness checklist

Public facts only. We never publish an approval probability.

Updated Oct 20, 2026

Primary endpoint metFavourable

Arcus Reports Positive ARC-20 Data for Casdatifan in 1L/2L/Late-Line ccRCC

Overall survival significant or trendingMixed

77%; 35 months

US / Western patient shareFavourable

226 of 464 sites in the United States

Advisory committee scheduledFavourable

No advisory committee announced

PDUFA date extendedUnknown

Manufacturing inspection recordUnknown

No public inspection record

Company language signals (label discussions)Unknown

Same-class precedentUnknown

Related companies

Each relationship is backed by the filing that stated it.

Taiho Not US-listedPartner

RCUSArcus BiosciencesOwner

Company press release Sep 22, 2026
SEC 8-K Oct 20, 2026
Company press release Oct 20, 2026

Verify every date against the linked primary source. Informational only. Not investment advice. SimianX is not affiliated with the FDA or the SEC.

Registered trials

Registry ID	Phase	Status	Primary completion	Enrollment	Sites
NCT07293351	Phase 1/2	Recruiting	Nov 28, 2029	474	17 of 95 sites in the United States
NCT07227415	Phase 1/2	Recruiting	Nov 2, 2027	224	160 of 183 sites in the United States
NCT07011719	Phase 3	Recruiting	Apr 1, 2028	720	46 of 183 sites in the United States
NCT07397611	Phase 2	Recruiting	Jan 31, 2028	32	3 of 3 sites in the United States